Document ZnNOgwemnXB36ewyKbQ8rEg7V

ff oCo o Attn: Bill Weppner and Dan Hakes, 3M 4fio[2000 em From: Cartes A AR ARE - 0633 Dear Bill and Dan, s1 ufbomuinsdsitoodnoafy'tsespthodnaetacailnl3usMesfulpoisnsheeslspiionngotrocsonhtarroplenonantdheclpaerrifflyusooromcehoefmiocuarlspraisordiitsycunseseedds ifnor my email message of April 7, 2000. As discussed today: 3undMernFeIedFRnAot)raelstuhbomuigth cwoepideosorfeqsuteusdtietshaatlyroeaudyprporvoivdiedaedcom0pErPehAen(es.ig.v,eubnidbelrioTgSraCpAhyo8(f6t)h,e studies already submitted so we can check this against our holdings >incotphieeDsoatfaacAudteequsaycstyeamincd trooxbiucsittyssutmumdiaersycgaunibdeanlciemidteedvetlootpheedkfeoyr tohrecrHiPtiVcalCshtauldlieensgaesPdreosgcrraimbe.d Under this approach all studies will limited to studies which (1) serve to be cited identify in a bibliographic lowest (i... most listing toxic) although full copies lethal dose values by can be dsiafmfeerernotutreo)utseusbmoirt(t2e)d report under observed (1). effects which differ from those seen in studies (using the s>yssktienmaincdtoexyieciitryri(ti.ationssutbumdiitescocpainesboefhatnhdelkeedyionracrmiatnicnaelrstcuodniseisstwehnitcwhitshertvheattoousteltionuetdtfhoer acute: ifrrroitmattihoonspeotreenptoiratleodfinthseucbhmeimtiecdalstaundideso)t.her iritation studies which show effects which differ c>oTnhdeucitneitdalprrieoqruteost19is76g,enwerealalsyk lfiomriabteidbltioosgtrudaipehsycolinsdtuincgtealdl dsutrudiinegsoarnadftfeorr 1f9ul7l6.copFioerssotfudsiteusdies dienvtehelofpomlelnotwailngtoexnidcpitoyi:ntimamrueanso:togxeincetiitcy;touxpictiatkye;/smuebtcahbroolniiscm;tocxhircointyi;crteopxriocdituyc/tciavrecitnooxgiceintiyc;ity; ss neurotoxicity. g ?3 >Regarding exposure the types found in the iUnsfeoramnadtiEoxn,powseuraereInmfoosrtmaitniteornesPtreodfiilne r(eUcEeIiPvi;ntghienUfEorImPathiaosn baenednduasteadotfo ~~ 3 2 Sstuupdpioerst (ShIuDmSanasasnedssemnevnitrsonimn etnhteaUlS))inacnldudiinnfgorfmulalticoonpioensorfesuslttusdoifesexwphoesrueraevaoirlambolneitaonrding 25 5 including details on procedures and methods used for sampling and analysis. We will take a TM close look at the white paper on exposure previously provided by 3M and get back to you with ~~ additional points where relevant. >Regarding PFOS, we request that 3M by April 24, 2000, send full copiesof studies relating to greenperroadtuicotnivsetutodxyicaintayl,ysdiesv,ehloupmmaenntmaolnitotxoirciintyg.(pehsapercmiaaclolkyindeettaiiclsso!-fainnacllyutdiicnagl tchheemreissutlrtysomfetthheod2saPnFdOsStu(days opurtoltionceodlsintomayllAopwriuls7toemeavaillumaetesssatguedi)esneaeldrseatdoybperosvuibdmeidt)t.edObtyheArpirniflo2r8m,at2i0o00n.on >Regarding other sulfonated perfluorochemicals appearing in Table 1 of 3M's March 1, 2000 1 white paper (as discussed in my April 7 email), 3M is asked to provide the requested information by May 19,2000. "2I6n,f2o0r0m0a,tiaonndosnhoPuFldOAb,e saucbamribtotxeydlaatsesduppeprlfelmueonrtoschteomyiocaulr,coismpreaqnuye'sstepdritoorbseubpmriosvsiidoendsbuynMdeary TSCA 8(e) 394 (not 8(c) 373/374 as otherwise discussed in my April 7 email message). cEoxncteipntueastodiaspcpulsysetdo athbiosvree,qtuheestrebqyueEsPtsAanfodrgiunifodramnacteiopnr.oviIfdeydouinhmavaeyaAnpyriglen7e,r2a0l0q0ueesmtaiiolns regarding this request, please contact me by email or phone (202-260-3749). 1 thank you in advance for your cooperation. Charles M. Auer, Director Chemical Officeof Control Division Pollution Prevention and Toxics'OPPTS/EPA